3:55 PM
 | 
Nov 03, 2009
 |  BC Extra  |  Top Story

Linaclotide meets Phase III endpoints

Ironwood Pharmaceuticals Inc. (Cambridge, Mass.) and partner Forest Laboratories Inc. (NYSE:FRX) said linaclotide met the primary endpoint and all secondary endpoints in two Phase III trials to...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >